The raw feed
Latest filings
Every transaction from every Form 4, as filed, newest first. Open-market buys (P) and sells (S) become signals; the rest is shown for completeness.
| Date | Company | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Erez Chimovits director | CConversion Common Stockindirect: See footnotes | +513,067 | - | - | 8,974,061 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Erez Chimovits director | CConversion Common Stockindirect: See footnotes | +256,448 | - | - | 9,230,509 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Erez Chimovits director | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -7,127,019 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Erez Chimovits director | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,333,975 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Erez Chimovits director | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -513,067 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Erez Chimovits director | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -256,448 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +10,690,530 | - | - | 10,690,530 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +2,000,962 | - | - | 12,691,492 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +769,601 | - | - | 13,461,093 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +564,187 | - | - | 14,025,280 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +7,127,019 | - | - | 7,127,019 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +1,333,975 | - | - | 8,460,994 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +513,067 | - | - | 8,974,061 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +256,448 | - | - | 9,230,509 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -10,690,530 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -2,000,962 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -769,601 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -564,187 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -7,127,019 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,333,975 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -513,067 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -256,448 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +10,690,530 | - | - | 10,690,530 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +2,000,962 | - | - | 12,691,492 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +769,601 | - | - | 13,461,093 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +564,187 | - | - | 14,025,280 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +7,127,019 | - | - | 7,127,019 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +1,333,975 | - | - | 8,460,994 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +513,067 | - | - | 8,974,061 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +256,448 | - | - | 9,230,509 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -10,690,530 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -2,000,962 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -769,601 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -564,187 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -7,127,019 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,333,975 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -513,067 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -256,448 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | WDAY Workday, Inc. | David A Duffield owner | CConversion Class A Common Stock10b5-1 | +98,971 | $0.00 | $0 | 204,020 | 12 d ago |
| Sep 28, 2026 | WDAY Workday, Inc. | David A Duffield owner | CConversion Class B Common Stockderivative10b5-1 | -98,971 | $0.00 | $0 | 35,778,260 | 12 d ago |
| Sep 24, 2026 | ATER Aterian, Inc. | David E. Lazar Chief Executive Officer | CConversion Common Stock | +1,300,530 | $0.00 | $0 | 8,038,030 | 13 d ago |
| Sep 24, 2026 | ATER Aterian, Inc. | David E. Lazar Chief Executive Officer | CConversion Series AA Convertible Non-Redeemable Preferred Stockderivative | -168,900 | $0.00 | $0 | 706,100 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | LAV Biosciences Fund V, L.P. owner | CConversion Common Stock | +8,908,775 | - | - | 8,908,775 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | LAV Biosciences Fund V, L.P. owner | CConversion Common Stock | +1,667,469 | - | - | 10,576,244 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | LAV Biosciences Fund V, L.P. owner | CConversion Common Stock | +513,067 | - | - | 11,089,311 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | LAV Biosciences Fund V, L.P. owner | CConversion Common Stock | +153,868 | - | - | 11,243,179 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | LAV Biosciences Fund V, L.P. owner | CConversion Common Stockindirect: By LAV Fund VI, L.P. | +307,738 | - | - | 307,738 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | LAV Biosciences Fund V, L.P. owner | CConversion Common Stockindirect: By LAV Fund VI Opportunities, L.P. | +307,738 | - | - | 307,738 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | LAV Biosciences Fund V, L.P. owner | CConversion Series A Preferred Stockderivative | -10,438,412 | $0.00 | $0 | 0 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | LAV Biosciences Fund V, L.P. owner | CConversion Series B Preferred Stockderivative | -1,953,774 | $0.00 | $0 | 0 | 13 d ago |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.